Format
Items per page

Send to:

Choose Destination

Search results

Items: 16

  • The following terms were not found in MeSH: H295R, NCI-H295R.
1.

NCI 83633 [Supplementary Concept]

a protein phosphatase 2C antagonist; structure in first source

Date introduced: March 4, 2009

2.

NCI 65828 [Supplementary Concept]

an angiogenin inhibitor and antineoplastic agent; structure in first source

Date introduced: August 31, 2002

3.

National Cancer Institute (U.S.)

Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.

Year introduced: 2008

4.

Pseudomyxoma Peritonei

A peritoneal adenocarcinoma characterized by build-up of MUCUS in the PERITONEAL CAVITY. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low grade mucinous neoplasm of the APPENDIX (NCI Thesaurus).

Year introduced: 1987

5.

rhEDI-8t protein, human [Supplementary Concept]

from the NCI domain of collagen VIII; has antiangiogenic activity

Date introduced: June 28, 2012

6.

9-O-demethyltrigonostemone [Supplementary Concept]

from the roots of Strophioblachia fimbricalyx; showed cytotoxicity against NCI-H187, KB, and MCF7 cancer cells; structure in first source

Date introduced: November 27, 2009

7.

NCI-172033 [Supplementary Concept]

structure in first source

Date introduced: October 5, 2009

8.

AZ703 compound [Supplementary Concept]

AZ703-induced apoptosis in NCI-H1299 cells was enhanced by small interfering RNA-mediated depletion of cdk9, which caused reduced levels of Mcl-1 and XIAP, suggesting that cdk2, cdk1, and cdk9 represent a rational subset of family members for drug targeting

Date introduced: February 17, 2006

9.

spongidepsin [Supplementary Concept]

a 13-membered depsipeptide isolated from the Vanuatu marine sponge Spongia sp., has shown potent antitumor properties against a variety of NCI tumor cell lines

Date introduced: March 31, 2005

10.

N-cyanomethyl-2-chloroisonicotinamide [Supplementary Concept]

structure in first source

Date introduced: October 23, 2002

11.
12.

NCI PB 93-C-207 protocol [Supplementary Concept]

chemotherapy protocol consisting of above cpds used in treatment of non-Hodgkin's lymphomas

Date introduced: June 16, 1997

13.

diethyl-n-butyltin(IV) trimethoxybenzoate [Supplementary Concept]

has in vitro cytotoxicity against 60 human NCI tumor cell lines

Date introduced: September 9, 1992

14.

di-n-butyltin(IV) trimethoxybenzoate [Supplementary Concept]

has in vitro cytotoxicity against 60 human NCI tumor cell lines

Date introduced: September 9, 1992

15.

CAV protocol [Supplementary Concept]

chemotherapy protocol consisting of cyclophosphamide, adriamycin, vincristine; CAV refers to first source; acronym ACV refers to second source; acronym ACO II was used in Klin Wochenschr 1982;60(16):829; acronym ACO was used in Onkology 1982;5(4):174; acronym DVC was used in Gan To Kagaku Ryoho 1984;11(4):888

Date introduced: June 18, 1982

16.

sparfosic acid [Supplementary Concept]

inhibitor of aspartate transcarbamylase

Date introduced: January 1, 1976

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Loading ...
Support Center